Medication Overuse Headache in 2026: Withdraw, Bridge, or Skip Straight to Anti-CGRP?

The Controversy

Medication overuse headache (MOH) sits at one of the most contested intersections in neurology. By ICHD-3 criteria, it requires ≥15 headache days/month for ≥3 months in the setting of regular acute-medication overuse — ≥10 days/month for triptans, opioids, ergots, or combination analgesics, ≥15 days/month for simple analgesics. It affects roughly 1–2% of the general population and somewhere between 11% and 70% of chronic migraine patients, depending on which clinic you walk into. That's an estimated 58 million people worldwide.

For decades, the orthodoxy was simple: detoxify first, prevent later. The patient was the problem; the overused drug was the perpetuator; withdrawal was the cure. That framework is now under siege from three directions — a landmark RCT that questioned the necessity of the order, a 2025 network meta-analysis that questioned whether withdrawal alone does anything at all, and six anti-CGRP datasets that questioned whether withdrawal is even a prerequisite for response.

So in 2026, when a patient with chronic migraine and triptan overuse walks into your clinic, what do you actually do? Three schools are now competing for that decision.

The Case For Each School

School A — Withdraw First (The Classical Position)

The canonical evidence is Carlsen 2020 (n=120), a three-arm trial that remains the cleanest comparison we have:

• Withdrawal + preventive from day 1: 96.8% MOH cure, 74.2% reverted to episodic, MMD −12.3
• Preventive alone: 74.3% cure, 60.0% reverted, MMD −9.9
• Withdrawal alone: 88.9% cure, 41.7% reverted, MMD −8.5

The signal favoring combined therapy on reversion to episodic was real (p=0.03). The classical school points to this and says: removing the offending agent and starting prevention nearly doubles the probability of returning to episodic headache compared with prevention alone. The drug truly is part of the disease.

School B — Bridge the Withdrawal

The bridging school accepts withdrawal as necessary but argues the misery of withdrawal itself is what drives early relapse. Tools include phenobarbital substitution for butalbital (30 mg ≡ 100 mg), clonidine taper for opioids, IV magnesium and antiemetics, greater occipital nerve blocks, and short-course steroids.

Braca 2024 (n=75) tested galcanezumab + prednisone (50 mg with 28-day taper) vs galcanezumab alone vs prednisone alone. Median MMD at 3 months: 7 vs 10 vs 15 (all p<0.001 vs baseline). Bridging steroids gave the biggest absolute reduction — but at significant side-effect cost (p=0.002), prompting the authors to recommend prednisone only in galcanezumab non-responders.

School C — Skip the Withdrawal Entirely

Six RCT-grade datasets now make this position respectable rather than reckless:

• Tepper 2019 — Erenumab CM/MO subgroup (n=274): MMD −6.6 vs −3.5 placebo; ≥50% responders 36% vs 18%; 71% switched off simple-analgesic overuse on 140 mg.
• Silberstein 2020 (HALO CM) — Fremanezumab MO subgroup (n=587, 51.9% of trial): monthly-dose MMD LSM Δ −2.4 vs placebo (quarterly −2.0; P<0.001); 60.6% reverted from MO to no-MO on monthly dosing vs 46.3% placebo. The effect was preserved in the without-MO subgroup — supporting the conclusion that the CGRP signal is independent of overuse status.
• Dodick 2021 (REGAIN) — Galcanezumab dropped MO prevalence from ~64% baseline to ~33% at month 3 (vs ~46% placebo).
• Lipton 2020 (PROMISE-2) — Eptinezumab in CM with the MO subgroup pre-specified: significant reductions in MMD vs placebo for the MO subgroup, with effect sizes paralleling the overall trial.
• Pozo-Rosich/Goadsby 2024 (PROGRESS) — Atogepant CM/MO subgroup (n=500): MMD LSMD −2.7 [−4.0, −1.4]; ≥50% responder OR 2.5; 61.9% no longer met MO criteria at 12 weeks. The first compelling oral, small-molecule data in this space.
• RESOLUTION 2026 — Eptinezumab + brief education intervention vs placebo + education (n=604), the first dedicated CM/MOH RCT: MMD −6.9 vs −3.7 over weeks 1–4 (difference −3.2; P<0.0001); 37.8% no longer met CM nor MOH criteria at weeks 1–4 vs 18.1% placebo (OR 3.3); 27.2% vs 12.7% sustained reversion at weeks 1–12 (OR 3.1). Note that the placebo arm also received structured education — we'll come back to that.

That last point is the most important — and most under-discussed — finding of 2026. We'll come back to it.

One more dataset deserves a place in this debate: MOTS 2022 (n=720), the largest randomized comparison in the medication-switching question. Patients with CM and acute-medication overuse received a preventive plus either (1) switching from the overused medication to an alternative used ≤2 d/week, or (2) continuation of the overused medication with no maximum limit. There was no difference in moderate-severe headache days at weeks 9–12 (9.3 vs 9.1; p=0.75). But the switching arm did reduce MO prevalence at 12 weeks (53% vs 73%; p<0.001) and lowered total acute-medication days (10.2 vs 14.7; p<0.001). The implication: prevention is doing the headache work; restriction does the medication work — and they're partially independent goals.

The Case Against Each School

Against "Withdraw First"

Liu/Wakerley's 2025 network meta-analysis (16 RCTs, ~3,000 patients, 12 strategies) is the most uncomfortable single document the classical school has had to read in years:

• Withdrawal + prevention + GON block: Δ MMD −10.6 (95% CI −15.0 to −6.2)
• Restriction + prevention + anti-CGRP(R): −8.47 (−12.8 to −4.2)
• Single-strategy prevention, anti-CGRP, or BoNT-A: significant but smaller
• Withdrawal alone: −2.77 (−5.74 to 0.20) — not statistically significant

Read that last line again. Withdrawal by itself, without an attached preventive or bridge, is statistically indistinguishable from no treatment. The classical "detox-only-then-see-what-happens" approach has no defensible evidence base in 2026.

Against "Bridge"

Bridging works, but it's a complexity tax. Braca's prednisone arm carried a measurably worse side-effect profile (p=0.002), and phenobarbital/clonidine tapers require infrastructure not available in most outpatient practices. The bridging school's strongest argument — that anti-CGRP plus steroid beats anti-CGRP alone — is actually an argument for combination therapy generally, not for steroid bridging specifically. Greater occipital nerve blocks may be doing the same job with less collateral damage.

Against "CGRP-First"

Before we celebrate, let's read the fine print on those six trials.

Tepper, HALO, REGAIN, PROGRESS, and PROMISE-2 were not designed to test MOH treatment. The MO-positive analyses in Tepper, REGAIN, and PROGRESS were pre-specified subgroups; the HALO CM analysis was post hoc. Either way, subgroup analyses are not the same as a dedicated trial. The exclusion criteria matter: PROGRESS used standard ICHD criteria but excluded opioid overuse in practice; the others variably excluded patients with opioid dependence, recent failed prevention, or psychiatric comorbidity. The trial says yes — but look at who was in the room.

Specialty headache centers report 50–70% MOH prevalence among chronic migraine patients, versus 15–18% in general migraine populations. The trial subgroups, recruited from specialty centers, are not representative of the broader CM-MOH universe — and they almost entirely exclude the patients who give us the most trouble: codeine/opioid overuse, butalbital dependence, prior multiple failed preventives.

And then there's RESOLUTION's placebo arm. Patients receiving only brief educational intervention achieved meaningful reductions in headache days and an 18% MOH reversion rate. That's not nothing — that's the floor under any anti-CGRP claim. The combined eptinezumab + education arm reached ~38% reversion. Real, but not transformational. Education does substantial work that the CGRP-evangelist position quietly attributes to the antibody.

What the Data Actually Shows

Strip away the school loyalties and a coherent picture emerges:

1. Withdrawal alone is dead. NMA 2025 effect size: −2.77 days, NS. Doing nothing else and just removing the drug is not a defensible 2026 strategy.

2. Anti-CGRP works without a washout. Six datasets, five molecules, consistent direction, effect sizes comparable to the no-MO subgroups. The sensitization-by-overuse hypothesis, in its strongest form ("you must remove the drug before the brain will respond"), is empirically wrong for most patients on most acute medications.

3. Combinations beat monotherapy. Liu NMA top tiers are all 3-element combinations. Carlsen's signal was combined > either alone. Braca's gal+pred > gal alone. MIND-CM 2023: usual care + mindfulness reached the primary endpoint (≥50% headache-frequency reduction at 12 months) in 78.4% vs 48.3% with usual care alone (p<0.0001).

4. Drug class still matters. Codeine-containing combos are the strongest predictor of relapse in long-term cohorts. Butalbital and opioid overuse have no dedicated CGRP RCT. The "MOH is one disease" assumption may be the field's most consequential unexamined premise.

5. Education has non-trivial independent effect. The RESOLUTION placebo arm tells us the brief educational intervention is doing real work. We just haven't been measuring it.

A 2026 Practical Algorithm

What this synthesis supports — recognizing that we still lack head-to-head trials of the strategies themselves:

• Anti-CGRP available + simple analgesic or triptan overuse: anti-CGRP mAb or atogepant + structured education + restrict to ≤2 d/week. No mandatory withdrawal. Anchor: RESOLUTION, Tepper, HALO, REGAIN, PROGRESS, PROMISE-2.
• Anti-CGRP unavailable or insurance-blocked: withdrawal + oral preventive starting day 1 (topiramate, propranolol, candesartan, or BoNT-A). Anchor: Carlsen 2020.
• Butalbital or opioid overuse, severe withdrawal anticipated: bridge with phenobarbital or clonidine taper + GON block + short steroid + start prevention + plan anti-CGRP at week 4–8. Consider inpatient. Anchor: Liu NMA W+P+Nb tier.
• Refractory or relapsed: add mindfulness program (MIND-CM), combine BoNT-A + atogepant, consider inpatient restart.
• Already on anti-CGRP, still overusing: add MOTS-style structured restriction — reduces MO prevalence even when headache days don't fully respond.

And reassess MO criteria at weeks 4, 12, and 24. The 1-year relapse rate is 20–40%; vigilance through year 1 is non-negotiable.

The Unresolved Questions

The 2026 stance I find defensible: education-anchored, drug-class-tailored, CGRP as the off-ramp — not the magic bullet, not a bystander. Combine 2–3 elements, not 1.

But several questions remain wide open, and clinicians should know exactly where the evidence runs out:

• No head-to-head trials of anti-CGRP alone vs anti-CGRP + structured withdrawal vs anti-CGRP + restriction. Every algorithm above is interpolation.
• Atogepant vs anti-CGRP mAbs in MOH — no comparator data, despite the access advantages of an oral gepant.
• Two-year and five-year MOH-free survival on chronic anti-CGRP — the single biggest evidence gap. We don't actually know what we're committing patients to.
• Opioid-MOH has no dedicated CGRP trial. The patients we most need data on are the ones excluded from the trials we have.
• Pediatric MOH — barely studied.
• Whether MOH is one disease or several drug-class-specific sensitization patterns — the "unsolved riddle in nociception" framing of the 2024 narrative reviews remains unsolved.

The classical neurologist who insists on detoxification first is wrong in 2026. The CGRP-evangelist who insists the antibody alone will sort it out is also wrong — RESOLUTION's placebo arm tells us so. The question isn't settled. Here's why that's actually a good thing: it means we're forced to think about each patient's drug class, comorbidity, access, and relapse risk rather than running them through a protocol. MOH may be the cleanest example in headache medicine of a disease where the algorithm is the patient.

The question I'd put to readers: If withdrawal alone has no proven benefit (Liu 2025), and anti-CGRP works without it (six datasets), and education does measurable independent work (RESOLUTION) — at what point do we stop calling MOH a disorder of the patient's behavior, and start calling it a disorder of our prescribing? And does that reframe change what we measure as success?